SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Progression on PD-1/PDL-1 Tx

Condition:   Solid Tumor Interventions:   Radiation: Stereotactic radiotherapy;   Other: Biological: humanized anti-PD-1 monoclonal antibody;   Other: Biological: humanized anti-PD-L1 monoclonal antibody Sponsors:   Virginia Commonwealth University;   National Cancer Institute (NCI) Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2tnUL0J
via IFTTT